Table 2.
Differences between relapsing patients and patients in complete continuous remission with respect to age, tumor size, lymph nodes, HER2/neu status, hormone receptor and chemotherapy
| CR | Rel | P | |
|---|---|---|---|
| Number of patients | 132 (75%) | 43 (25%) | |
| Mean age | 51 | 53 | ns |
| Tumor size | |||
| T1 | 71 (54%) | 20 (46%) | 0.45 ns |
| T2> | 49 (37%) | 18 (42%) | |
| n.a. | 12 (9%) | 5 (12%) | |
| Node | |||
| N0 | 87 (66%) | 16 (37%) | 0.005 |
| N1> | 33 (25%) | 23 (54%) | |
| n.a. | 12 (9%) | 4 (9%) | |
| Her2/neu status | |||
| Negative | 62 (47%) | 21 (49%) | ns |
| Positive | 31 (23%) | 11 (25.5%) | |
| n.a. | 39 (30%) | 11 (25.5%) | |
| Hormone receptor | |||
| Negative | 8 (6%) | 1 (2%) | ns |
| Positive | 115 (87%) | 40 (93%) | |
| n.a. | 9 (7%) | 2 (5%) | |
| Chemotherapy | |||
| Adj | 51 (39%) | 22 (51%) | ns |
| Neo | 31 (23%) | 10 (23%) | |
| None | 38 (29%) | 8 (19%) | 0.12 ns |
| n.a. | 12 (9%) | 3 (7%) | |
| Patients with CETC analysis | 121 (82%) | 26 (18%) | |
| Decrease | 64 (52%) | 2 (11%) | <0.0001 |
| Increase | 37 (30%) | 21 (81%) | |
| No change | 20 (16%) | 3 (8%) | |
CR complete remission, Rel relapse, adj adjuvant, neo neoadjuvant, n.a. not analyzed